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A B S T R A C T
The traditional biomarkers, CK-MB and troponins, used for the diagnosis of myo-
cardial ischemia and the risk stratification of patients with acute coronary syndromes 
(ACS) are of limited use mainly because they require some degree of necrosis in order 
to become detectable. Based on the knowledge gained into the pathophysiology of 
ACS, several new biomarkers have been developed. Brain natriuretic peptides (BNP 
and NT-proBNP) as markers of hemodynamic stress have shown in several studies 
a good diagnostic and prognostic performance. C-reactive protein (CRP) reflecting 
systemic inflammation, has mainly a role as risk stratifier. Ischemia modified albumin 
(IMA) a pure ischemia marker may offer a substantial aid in diagnosing an acute 
coronary event in patients with negative troponin. Finally, myeloperoxidase (MPO), a 
marker of oxidative stress, may also contribute to the diagnosis of ischemia although 
this is not yet supported by a fair amount of data. Nevertheless, although highly sen-
sitive, these new biomarkers are not specific enough and a multi-marker approach 
seems the most appropriate strategy for diagnosis of myocardial ischemia and for as-
sessing the risk of an adverse outcome in patients with an acute coronary syndrome.
I N T R O D U C T I O N
Establishing a diagnosis of myocardial ischemia in the clinical setting remains a 
challenging task. In addition to history of chest pain and abnormal electrocardiographic 
(ECG) changes, laboratory evidence of myonecrosis has always been an integral part 
of the initial diagnostic work up of a suspected acute coronary syndrome (ACS) [1]. 
Unfortunately, the myonecrosis markers, myoglobin, creatine kinase (CK-MB) and 
the troponins (Tns), cannot by definition help clinicians in the assessment of patients 
with stable or unstable angina where ischemia is not accompanied most of the time 
by myocardial necrosis. In addition, myocardial necrosis is time-dependent, such that 
these highly sensitive and specific markers might give negative results on admission 
but give positive results hours later [2]. As such, the usefulness of the conventional 
biomarkers of myocardial necrosis for the confident exclusion of the diagnosis of 
myocardial ischemia at the time of admission remains limited. Markers able to identify 
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patients with myocardial ischemia without infarction might 
play an important role in the clinical setting since among those 
patients with a definite ACS, early treatment may reduce the 
extent of myocardial injury, and thus rapid diagnosis and 
initiation of therapy is a central tenet of management [3]. 
In addition, given the increasing array of treatments for the 
heterogeneous population of patients admitted with ACS, ef-
fective risk stratification and targeting of therapy have become 
a focus of contemporary management of clinically evident 
myocardial ischemia [4]. As such, the objectives of the initial 
assessment are twofold: (a) to assess the probability that the 
patient’s symptoms are related to acute coronary ischemia 
(i.e. establish the diagnosis) and (b) to assess the patient’s 
risk of recurrent cardiac events, including death and recur-
rent ischemia (define the prognosis). In this review, the role 
of some newly developed biochemical markers in establishing 
the diagnosis and prognosis of myocardial ischemia will be 
briefly presented.
B R A I N  N A T R I U R E T I C  P E P T I D E S  ( B N P )
The brain natriuretic peptide (BNP) is synthesized by 
cardiac myocytes when left ventricular wall stress increases 
[5]. After secretion, the pro-hormone is cleaved to the biologi-
cally active hormone (BNP) and to the inactive N-terminal 
fragment (NT-proBNP). Enough evidence already exists that 
measuring the blood level of either one of these molecules 
improves the ability to diagnose or exclude heart failure as the 
cause of acute dyspnea [6,7]. Moreover, BNP measurement 
provides useful prognostic information on mortality risk in 
patients with heart failure [8,9]. However, only recently BNP 
has also been recognized as a potential diagnostic marker of 
myocardial ischemia as well as a prognostic indicator in pa-
tients with coronary artery disease. Jernberg et al [10] collected 
blood samples of 775 acute chest pain patients without ST-seg-
ment elevation upon admission to the coronary care unit and 
showed that patients with an acute myocardial infarction (MI) 
had significantly higher median BNP levels than patients with 
unstable angina or non-cardiac chest pain. Bassan et al [11] 
studied prospectively 631 patients presenting to the emergency 
department with chest pain and without ST-elevation in the 
ECG. Sensitivity of admission BNP for acute MI (cut off value 
of 100 pg/ml) was significantly higher than CPK-MB and TnI 
(70.8% vs. 45.8% vs. 50.7% respectively). However, specificity 
was substantially lower (70% vs. 98%). Simultaneous use 
of all 3 markers significantly improved sensitivity to 87.3% 
and negative predictive value to 97.3%. According to these 
data, the use of natriuretic peptides in the emergency depart-
ment as a simple aid for deciding whether a chestpain patient 
should be admitted to the hospital or can safely be discharged 
home seems very promising. Nevertheless, this marker needs 
to be more thoroughly investigated before being accepted as 
a clinically useful tool.
On the other hand, more research has been conducted 
regarding the prognostic role of natriuretic peptides in the 
setting of acute or chronic myocardial ischemia. Levels of BNP 
and NT-proBNP have shown to correlate with left ventricular 
dilatation, remodeling, and dysfunction, as well as congestive 
heart failure and death among patients presenting with acute 
MI [12]. Beyond that, several studies have now demonstrated 
a robust association between BNP or NT-proBNP and the 
short- and long-term risk of death across the spectrum of 
non-ST-elevation ACS including patients without myocardial 
necrosis or clinical evidence of heart failure. In the most recent 
of those studies, Jarai et al [13] showed that Nt-proBNP along 
with TnI were independent predictors of 2-year mortality in 
120 patients with unstable angina. These findings confirmed 
the results of previous studies which had similarly shown that 
both BNP and NT- proBNP offered significant information 
about short and long term prognosis in patients with unstable 
angina and that this information was independent of the left 
ventricular systolic function [14-17].
Finally, another very interesting emerging concept is that 
natriuretic peptides may have a prognostic role not only in 
the acute ischemia setting but also in patients with chronic 
ischemic heart disease. Thus, Ndrepepa et al [18] recently 
published the results of their study which included 1059 pa-
tients with chronic stable angina. NT-proBNP levels were the 
strongest correlate of 5-year mortality in this population out-
weighing other significant variables like age, New York Heart 
Association (NYHA) class and CRP. In this study, plasma 
NT-proBNP enabled the identification of a group of patients 
who were at particularly high risk for death after coronary 
intervention with stenting. Similar findings were reported 
by the AtheroGene study investigators who prospectively 
followed 904 patients with stable and unstable angina for 
2 years [19]. Baseline NT-proBNP was significantly higher 
among individuals with cardiovascular events compared 
with those without. In the subgroup of patients with stable 
angina, those within the top quartile had a 3.7-fold increase 
in cardiovascular risk. To further expand the prognostic role 
of natriuretic peptides even in patients with disease in other 
than the coronaries vascular beds, Campbell et al [20] showed 
that NT-proBNP levels were able to predict MI in subjects who 
had experienced a cerebrovascular event. In this nested case-
control study which was part of the Perindropril Protection 
Against Recurrent Stroke Study (PROGRESS), NT-proBNP 
was found superior to CRP and to renin levels in predict-
ing cardiovascular risk. The mechanism responsible for the 
increased levels of brain natriuretic peptides in myocardial 
ischemia remains unclear. Increased ventricular wall stress 
due to ischemia induced systolic or diastolic dysfunction cer-
tainly plays a role. Indeed, Richards et al [21] recently showed 
that both BNP and NT-proBNP closely correlated with left 
ventricular ejection fraction in a large population with stable 
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ischemic heart disease being at the same time independent 
predictors of 12-month total mortality and admission to the 
hospital with heart failure. However, evidence also exists 
that ischemia may itself promote BNP gene expression in the 
hypoxic myocardium of the left ventricle [22].
C - R E A C T I V E  P R O T E I N
C-reactive protein (CRP) is the inflammatory marker 
receiving the most attention to date as a prognostic indica-
tor of coronary artery disease. It is an acute phase reactant 
normally present in plasma at low levels, and increases >100-
fold in response to inflammatory stimuli. It is produced by 
hepatocytes in response to stimulation by interleukin-6. It 
is also produced by human coronary artery smooth muscle 
cells [23]. Although initially considered only a marker of 
inflammation, CRP itself has been shown to possess pro-
inflammatory and pro-atherogenic properties. It stimulates 
endothelial cells to express adhesion molecules and secrete 
cytokines [24,25] and it decreases the expression of endothelial 
NO synthase [26,27]. CRP accumulates in macrophage-rich 
regions of nascent atherosclerotic lesions and activates the 
macrophages to express cytokines and tissue factor, while 
enhancing macrophage uptake of LDL [28]. It also amplifies 
pro-inflammatory effects of several other mediators including 
endotoxin [29,30]. In a post-mortem study of 302 autopsies 
of men and women with atherosclerosis, median CRP levels 
were higher with acute plaque rupture than in stable plaques or 
controls [31]. The levels correlated with the staining intensity 
for CRP in macrophages and the lipid core of plaques, and 
it increased with the number of thin cap atheromas found in 
coronary arteries. Plasma CRP levels at the upper end of the 
reference range in apparently healthy men and women, in the 
absence of other sources of inflammation, correlated with 
increased risk of future cardiovascular events, including MI, 
peripheral vascular disease with intermittent claudication and 
stroke [32]. These data support the view that systemic CRP 
accurately reflects the number of vulnerable atherosclerotic 
plaques. A decade ago Liuzzo et al [33] reported that patients 
with unstable angina and elevated levels of CRP (3 mg/dl) had 
higher rates of death, acute MI and need for revascularization 
compared to patients without elevated levels. Moreover, this 
increased risk may be evident as early as 14 days after pre-
sentation [34]. These findings have been confirmed by more 
recent data. The CAPTURE trial found that although only 
TnT was predictive in the first 72-hour period, both CRP and 
TnT were predictors of risk within 6 months [35]. The FRISC 
Investigators reported that the risk associated with elevated 
CRP levels at the time of an index ACS event continued to 
increase for several years afterwards [36]. Mueller et al [37] 
reported that in ACS patients who were treated with very early 
revascularization, CRP was a strong independent predictor 
of both short-term and long-term mortality. However, not ev-
erybody agrees that CRP levels are of significant prognostic 
importance. Lee et al [38] recently showed that CRP did fairly 
worse compared to interleukin-6 and total homocystein in 
predicting coronary artery disease related death in a cohort 
of 1117 consecutive patients undergoing selective coronary 
angiography. Nevertheless, most of the experts in the field 
seem to agree that the role of CRP as a prognostic marker in 
patients with an ACS appears to be established.
Unfortunately, despite its prognostic importance, the 
contribution of CRP to the diagnosis of coronary ischemia is 
rather poor. This has been confirmed by a recently published 
systemic review of the potential use of 22 protein markers in 
low risk patients presented to the emergency department with 
chest pain. CRP demonstrated an area under the curve of only 
0.61 in the summary Receiver Operator Characteristic (ROC) 
curve analysis with a pooled diagnostic odds ratio of 1.81 [39]. 
This has to be attributed to the very low specificity of this 
biomarker. Daily fluctuations in basal CRP levels are signifi-
cant and are 4–6 times greater than cholesterol fluctuations. 
CRP levels are transiently elevated for 2–3 weeks following a 
major infection or trauma. Chronic inflammatory conditions 
like rheumatoid arthritis or lupus will also confuse interpreta-
tion of CRP levels. Minor inflammatory stimuli, such as viral 
infection, skin lacerations and some noninflammatory states 
(e.g., a low level of physical activity, aging, chronic fatigue, 
high protein diets, alcohol consumption and depression), are 
also known to influence CRP. These limitations make the 
CRP practically useless in differentiating among patients with 
chest pain those who have myocardial ischemia. Moreover, 
knowledge of these other causes of CRP fluctuations can help 
interpret its value for cardiovascular risk assessment as well.
I S C H E M I A  M O D I F I E D  A L B U M I N  ( I M A )
Ischemia modified albumin (IMA) is a new marker of tran-
sient myocardial ischemia. IMA is measured by the Albumin 
Cobalt Binding (ACB) test, which measures the binding capac-
ity of exogenous cobalt to the N-terminus of human albumin. 
In the presence of myocardial ischemia, structural changes 
take place in the N-terminus of albumin that rapidly reduce 
its binding capacity for transition metal ions. These changes 
in the N-terminus of human albumin are attributed, among 
other factors, to ischemia/reperfusion mediators, hypoxia, and 
acidosis. There is no correlation between the ACB test results 
and human serum albumin levels in normal range. Studies 
have shown that IMA is highly sensitive for the identification 
of ACS and, in combination with the ECG and troponin, has 
both high sensitivity and negative predictive value. IMA has 
also been shown to be elevated in patients after coronary 
angioplasty as a result of ischemia reperfusion injury.
Unlike troponin, a marker of ongoing myocardial injury, 
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IMA is a marker of impending myocyte necrosis. During 
ischemia, free-radical damage alters the ability of albumin 
to bind cobalt. Using a colour indicator (dithiotreitol) to detect 
added cobalt, the level of such altered albumin in serum can be 
quantitated [40]. IMA has been shown to rise within minutes 
after the onset of ischemia, stay elevated for 6 to 12 hours, and 
return to normal within 24 hours. Furthermore, IMA has been 
shown to predict with high sensitivity subsequent elevation in 
the Tns in the clinical setting [41]. Blood levels of IMA rise in 
patients who develop ischemia during percutaneous coronary 
intervention [42,43]. IMA levels during balloon angioplasty 
are related to number, pressure, and duration of inflations, 
suggesting that IMA reflects the magnitude and duration of 
ischemia induced during percutaneous coronary intervention 
and is not simply a marker of free radical damage.
Moreover, according to recent studies, IMA has twice 
the sensitivity of an ECG and four times the sensitivity of 
troponin to detect patients with ACS at time of presentation; 
this is particularly evident in those patients with unstable 
angina, which is difficult to diagnose with other diagnostic 
methods. Sinha et al [44] evaluated IMA in conjunction with 
ECG changes and cardiac TnT levels in 208 patients present-
ing to the emergency department within 3 hours of the onset 
of acute chest pain. In the whole patient group, sensitivity of 
IMA at presentation for an ischemic origin of chest pain was 
82%, compared with 45% of ECG and 20% of TnT. IMA 
used together with troponin T or ECG, had a sensitivity of 
90% and 92%, respectively. Similarly, Roy et al [45] showed 
that in 131 patients presenting to the emergency department 
with symptoms suggestive of acute myocardial ischemia but 
with normal or non-diagnostic ECGs, IMA levels >93.5 U/
ml demonstrated a sensitivity and specificity of 75% for the 
diagnosis of ACS with an area under the ROC curve 0.78. 
Moreover, in combination with cardiac TnT levels >0.05 ng/
ml, the sensitivity increased to 92.2%. These findings were 
confirmed by the recently published results of Anwaruddin 
et al [46] who measured IMA along with standard biomarkers 
(myoglobin, CK-MB and TnI) in 200 patients with suspected 
myocardial ischemia admitted to the emergency department. 
In this patient population, the myoglobin–CK-MB–TnI triad 
had a sensitivity of 57% for detecting myocardial ischemia. 
The combination of IMA–myoglobin–CK-MB–TnI increased 
the sensitivity for detecting ischemia to 97%, with a negative 
predictive value of 92%. It should be noted however, that 
IMA alone was somewhat poorly specific for the presence of 
ischemia (specificity: 31%). Given its high negative predictive 
value as supported by the current evidence, the test has been 
approved by the FDA as a “rule-out” marker of myocardial 
ischemia. But some questions about how timing affects its 
performance also persist [47]. The change to albumin bind-
ing occurs very quickly but it also seems to disappear quickly 
(within 2-3 hours of the ischemic event). The exact mechanism 
of the initial alteration in cobalt binding and the reason for 
its rapid disappearance is unknown. This limits IMA’s use-
fulness as an additional marker in patients whose Tn level is 
only slightly elevated using the 99th percentile cut-off (and, 
therefore, possibly a false positive). If myocardial ischemia was 
the cause of the slight Tn elevation, IMA probably would have 
normalized by the time that Tn was elevated. Also, IMA may 
be falsely elevated (as far as myocardial ischemia is concerned) 
due to ischemia in other parts of the body [48].
Finally, the use of IMA as a risk stratifier in patients with 
acute or chronic ischemia has not been extensively evaluated. 
In the only study published so far, IMA was a poor predictor 
of serious cardiac outcomes in short term (72 hours of fol-
low-up) [49]. Nevertheless, this was a rather small study of 
189 patients and for a definite answer about the prognostic 
role of this new biomarker, further evaluation in larger trials 
seems necessary.
M Y E L O P E R O X I D A S E  ( M P O )
First identified within human atherosclerotic plaque nearly 
a decade ago [50], myeloperoxidase (MPO) has emerged as an 
important potential participant in the atherosclerotic process. 
MPO, a member of the heme peroxidase superfamily, gener-
ates reactive oxidants and diffusible radical species as part 
of its normal function in innate host defenses [51] A unique 
activity of MPO is its ability to use the halide chloride as 
co-substrate with hydrogen peroxide to generate chlorinating 
oxidants such as hypochlorous acid (HOCl), a potent antimi-
crobicidal agent [52]. MPO, and specific chlorinated protein 
and lipid oxidation products, are all markedly enriched within 
human atheroma. Leukocytes use MPO to generate oxidants 
capable of initiating lipid peroxidation [53] including conver-
sion of LDL into an atherogenic form recognized by macro-
phage scavenger receptors [54]. MPO may also contribute to 
the atherosclerotic process by promoting endothelial dysfunc-
tion, by virtue of its capacity to catalytically consume nitric 
oxide as a substrate in vitro [55] and in vivo [56], resulting in 
formation of nitric oxide–derived oxidants [57].
Indeed, recent clinical studies demonstrate that systemic 
levels of MPO serve as a strong and independent predictor 
of endothelial dysfunction in subjects [58], as well as angio-
graphic evidence of coronary artery disease [59]. Finally, re-
cent human genetic studies support a potential role for MPO 
in coronary artery disease because MPO deficiency in subjects 
is reportedly cardioprotective [60], and individuals possess-
ing a functional polymorphism associated with approximately 
two-fold decrease in MPO expression have reduced cardiac 
risks [61,62]. Given the increasing volume of pre-clinical and 
clinical data about the association of this enzyme with oxida-
tion, atherogenesis and possibly plaque rupture, clinical trials 
have been initiated to assess its validity as a diagnostic and 
prognostic marker of myocardial ischemia.
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In a landmark study, Brennan et al [63] measured base-
line levels of MPO, troponin T, and CRP in 604 chest-pain 
patients. To establish normal MPO levels, researchers also 
obtained measurements from 115 healthy volunteers without 
coronary artery disease. MPO levels were higher in patients 
who had an MI within 16 hours after presentation than in 
patients who did not. An elevated level predicted risk even in 
patients with normal initial troponin levels and irrespective 
of the time between symptom onset and presentation. The 
risk increased with increasing quartiles of MPO level. Most 
important, elevated levels at presentation predicted the risk 
for major coronary events at 30 days and at 6 months. The ad-
justed odds ratio for patients in the highest quartile compared 
with patients in the lowest quartile was 4.7. MPO was found 
to be a stronger predictor than CRP. Last year, based mainly 
on the results of this study, FDA approved an enzyme-linked 
immunosorbent assay (CardioMPO) for the quantitative de-
termination of MPO in human plasma. However, the general 
feeling of the medical community is that further studies are 
needed to gain more insight into the quantity and quality of 
information offered by this very promising new biomarker.
C O N C L U S I O N S
Acute coronary syndrome (ACS) is the final step of a 
complex pathophysiologic process including 1) progres-
sive mechanical obstruction due to atheroma formation, 
2) dynamic obstruction due to vasoconstriction, 3) plaque 
rupture with acute thrombosis as a consequence of oxidative 
stress and inflammation, 4) cardiac myocyte ischemia and 
necrosis, and 5) hemodynamic and ventricular wall stress. 
The better understanding of this whole process has led to 
the emergence of novel, sensitive biomarkers representing 
all the above pathophysiologic steps (Figure 1). There is 
growing evidence that these markers may become valuable 
for the diagnosis of ischemia and for assessing the risk of 
short and long term adverse outcome in patients presenting 
to the emergency department and to the outpatient clinic with 
symptoms suggestive of an ACS. However, these patients may 
vary substantially with respect to the relative contribution of 
each pathophysiologic step in the individual clinical picture. 
Accordingly, the relative importance of each biomarker may 
also vary in different patients. Moreover, both old and new bio-
markers, although sensitive, lack the specificity needed to gain 
widespread clinical application as a single marker of disease. 
Thus, a multi-marker strategy employing a pathophysiologi-
cally diverse set of biomarkers seems the most appropriate 
to lead ultimately to the best therapeutic strategy for the 
individual patient [64]. Nevertheless, further work needs to 
be done to define the optimal weighing of each biomarker for 
diagnosis and prognosis of myocardial ischemia and to assess 
the appropriate therapeutic responses to different patterns of 
biomarker elevation in ACS.
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